{'52WeekChange': -0.28981084,
 'SandP52WeekChange': 0.0644362,
 'address1': '1550 East Gude Drive',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 23.29,
 'askSize': 900,
 'averageDailyVolume10Day': 436300,
 'averageVolume': 524741,
 'averageVolume10days': 436300,
 'beta': 1.639775,
 'beta3Year': None,
 'bid': 23,
 'bidSize': 800,
 'bookValue': 11.675,
 'category': None,
 'circulatingSupply': None,
 'city': 'Rockville',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 23.9,
 'dayLow': 22.98,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': 0.173,
 'enterpriseToEbitda': 7.589,
 'enterpriseToRevenue': 2.997,
 'enterpriseValue': 1205720960,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 23.772858,
 'fiftyTwoWeekHigh': 34.11,
 'fiftyTwoWeekLow': 13.12,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 47674105,
 'forwardEps': 1.66,
 'forwardPE': 14.024097,
 'fromCurrency': None,
 'fullTimeEmployees': 464,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.03433,
 'heldPercentInstitutions': 1.03223,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/supernus.com',
 'longBusinessSummary': 'Supernus Pharmaceuticals, Inc., a pharmaceutical '
                        'company, focuses on the development and '
                        'commercialization of products for the treatment of '
                        'central nervous system diseases in the United States. '
                        'It offers Oxtellar XR, an extended-release '
                        'oxcarbazepine for use in the treatment of epilepsy; '
                        'and Trokendi XR, an extended-release topiramate, '
                        'which is used for the treatment of epilepsy and '
                        "migraine. The company's product candidates comprise "
                        'SPN-812, a viloxazine hydrochloride, which is in '
                        'Phase III clinical trial that is used for the '
                        'treatment of attention deficit hyperactivity disorder '
                        '(ADHD); SPN-810, a molindone hydrochloride that is in '
                        'Phase III clinical trial for the treatment of '
                        'impulsive aggression in patients with ADHD; SPN-809, '
                        'a viloxazine hydrochloride, which is in Phase II '
                        'ready clinical trial for the treatment of depression; '
                        'SPN-604 extended release oxcarbazepine for bipolar; '
                        'and SPN-817 that is in phase I clinical trial for '
                        'treating epilepsy. The company markets its products '
                        'through wholesalers and distributors. Supernus '
                        'Pharmaceuticals, Inc. was founded in 2005 and is '
                        'based in Rockville, Maryland.',
 'longName': 'Supernus Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 1223100928,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_422832',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 116234000,
 'nextFiscalYearEnd': 1640908800,
 'open': 23.75,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.45,
 'phone': '301 838 2500',
 'previousClose': 23.75,
 'priceHint': 2,
 'priceToBook': 1.9940042,
 'priceToSalesTrailing12Months': 3.0405958,
 'profitMargins': 0.28895,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 23.9,
 'regularMarketDayLow': 22.98,
 'regularMarketOpen': 23.75,
 'regularMarketPreviousClose': 23.75,
 'regularMarketPrice': 23.75,
 'regularMarketVolume': 265311,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 52538700,
 'sharesPercentSharesOut': 0.0849,
 'sharesShort': 4460613,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4206578,
 'shortName': 'Supernus Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.1271,
 'shortRatio': 9.1,
 'startDate': None,
 'state': 'MD',
 'strikePrice': None,
 'symbol': 'SUPN',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 2.161,
 'trailingPE': 10.772791,
 'twoHundredDayAverage': 21.79403,
 'volume': 265311,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.supernus.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '20850'}